The Clinical Trial College (CT College) ensures that the ethical assessment of clinical trials on medicinal products for human use is carried out in Belgium :
The safety of the participants in the clinical trials is essential in this regard.
As described in the law of 7 May 2017, the mission of the CT-College is as follows:
 Federal Agency for Medicines and Health Products
The CT College is an independent body set up within the FPS for Public Health, Food Chain Safety and Environment (FPS HFCSE).
How are we organized?
Katelijne Anciaux (NL)
Sébastien Vanhiesbecq (FR)
Julien Frgacic (FR)
Board (to be appointed)
Expert in Quality control systems
Doctor with experience in clinical tests
Links to Belgian legislation:
Links to European legislation:
On the website of the European Commission
PDF version in English
To prepare the implementation of the CTR in Belgium, a number of clinical trial applications have been submitted by sponsors to the FAMHP as pilot projects since May 2017. The procedure to approve clinical trials complies with the national legislation of 7 May 2004, but the application dossier as well as the assessment follow the spirit of the new European Regulation and the Belgian law of 7 May 2017.
The administrative staff of the CT-College works during our pilot projects according to the tasks and competences described. You will find more information about this pilot project on the FAMHP’s website.
Along with the administrative staff of the CT-College and with the FAMHP, a few members of fully recognized ethics committees contribute to the procedures for implementing the CTR in Belgium.
Along with the administrative staff of the CT-College and with BAREC, a few members of fully recognized ethics committees, representatives of patient organisations and Pharma.be
contribute to the revision of templates for the Informed Consent Form.
 Clinical Trial Regulation
 Belgian Association of Research Ethics Committees
This presentation gives more information:
Implementation of CTR in Belgium and the impact on the ethical review process
General mailbox: email@example.com
Informatiebrochure voor interventionele studies met geneesmiddel bij volwassen patiënten (pdf)
Brochure d’information relative aux études cliniques interventionnelles sur des patients adultes
Model ICF for interventional clinical trials with IMP on adult patients
Example – The trial at a glance
Information for ethics committees and sponsors on the informed consent procedure in trials ongoing at or completed before 25th may 2018 (pdf)
ANNEX to the “Information for ethics committees and sponsors on the informed consent procedure in trials ongoing at or completed before 25th May 2018” (docx)
Implementation of CTR in Belgium and the impact on the ethical review process (pdf)
This document contains FAQs on the IC procedure in trials ongoing at or completed before the implementation of the GDPR.
A link to the English version of the annex has been added on 04/...
This presentation gives you more information on how the CTR has an impact on :
A new template for the Informed Consent Form (ICF) for interventional clinical trials with an investigational medicinal product on adult patients was prepared by a dedicated working group. This working group consisted of representatives of BAREC (Belgian Association of Research Ethics Committees), pharma.be (the Belgian association of the innovative (bio)pharmaceutical industry) and patient organizations, and was coordinated by the CT-College at the FPS Health Food chain safety and Environment. During the review process of the proposed template the feedback on the content and format was also provided by laypersons.
Sponsors are highly recommended to use the template, when preparing the ICF(s) for all new initial interventional clinical trials on adult patients. During the next six months a transitional period will be in place during which both the old and the new template can be used. From 1st January 2020, the ethics committees will require that only the new template is used by all sponsors.
Questions on the use of this template may be sent to firstname.lastname@example.org”. Please mention “ICF_Template” in the subject of your mail.
This new template for the Informed Consent Form (ICF) for interventional clinical trials with an investigational medicinal product on adult patients was prepared by a dedicated working group. This...
On 20/03/2020, a European guidance was published on Eudralex.
This document will provide directions to sponsors and investigators on the subject of:
This guidance is supported by the FAMHP, the CT-College and Barec.
On 25/03/2020, a national guidance was published on the website van the FAMHP. This national guidance is to be read in conjunction with the latest version of the European guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic.
The national guidance is the result of a collaboration between the FAMHP, the CT-College, Barec and some clinical trial sites. The guidance is applicable at the time of publication and complements the European guidelines. The document will provide directions to clinical trial sponsors in the management of:
This national guideline will be regularly adapted to the evolution of the pandemic.
Press release of 21 April 2017 on the publication of the law on clinical trials with medicinal products for human use.
Information session for fully recognized ethics committees wishing to take part in the pilot project: